Licensing Opportunity Contact Form
Submission of this form should not be interpreted as an offer to license technology. All licenses are subject to negotiation and availablility of the intellectual property for licensing. This form is intended for indications of interest only.

Search/Browse Tech



ViralFx is an integrated approach to the diagnosis and treatment of SARS-CoV-2 that is accurate, rapid, repeatable, and easily deployed


In pandemic scenarios, the capacity to complete laboratory diagnostic tests can be overwhelmed due to the need for specialized equipment and highly trained personnel to perform the complex workflows for detection of viral RNA. To address this challenge, an integrated antiviral diagnostic solution developed by Sandia can improve our nation’s ability to identify and rapidly respond to pandemic outbreaks and future emerging pathogens.

ViralFx integrates several Sandia technologies into a powerful and comprehensive solution ready for commercialization. QUASR (Quenching of Unincorporated Amplification Signal Reporters) is a technique to significantly enhance the favorable characteristics of LAMP (Loop-mediated Isothermal Amplification). SmartLAMP is a smartphone-based deployable diagnostic device to quickly assess potentially dangerous public health situations. When combined with Sandia’s portable SpinDx platform, which offers rapid detection of viral and host antigens without the need for sample preparation, ViralFx can enable the positive identification of SARS-CoV-2, rules out influenza or other coronaviruses, and diagnoses COVID-19 at all stages of the disease.

ViralFx may improve healthcare outcomes, minimize the strain on medical providers, maximize provider capacity to treat patients, improve dataset fidelity related to virus spread, and ultimately reduce the potential of spreading the virus, thus saving countless lives.


  • Low-cost, portable instrumentation that can be controlled by a smartphone
  • Simplified workflow eliminates need for advanced technical training
  • Rapid detection (results within 30 minutes) without need for sample preparation
  • Diagnoses COVID-19 at all stages of disease
  • Positively identifies SARS-CoV-2 and rules out influenza or other coronaviruses

Applications and Industries

  • Detection of viral and host antigens
  • Determination of disease treatment’s effectiveness
  • Prevention of future outbreaks

Additional Information

Related technologies:

Intellectual Property

ID Number
Patent Number
Systems, devices, and methods for agglutination assays using sedimentation 9,244,065 01/26/2016
System and method for detecting components of a mixture including tooth elements for alignment 9,500,579 11/22/2016
Microfluidic devices, systems, and methods for quantifying particles using centrifugal force 9,186,668 11/17/2015
Devices, systems, and methods for conducting assays with improved sensitivity using sedimentation 9,304,129 04/05/2016
Devices, systems, and methods for conducting sandwich assays using sedimentation 8,945,914 02/03/2015
Devices, systems, and methods for conducting assays with improved sensitivity using sedimentation 8,962,346 02/24/2015
Technology IDSD# 12060, multiple additionalDevelopment StageDevelopment - TRL 5AvailabilityAvailablePublished04/29/2021Last Updated04/29/2021